Database : MEDLINE
Search on : ipodate [Words]
References found : 188 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 19 go to page                         

  1 / 188 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 25144248
[Au] Autor:Duboisset J; Matar G; Besson F; Ficheux D; Benichou E; Russier-Antoine I; Jonin Ch; Brevet PF
[Ad] Address:Institut Lumière Matière, ILM UMR CNRS 5306, Université Claude Bernard Lyon 1 , 10 Rue Ada Byron, 69622 Villeurbanne Cedex, France.
[Ti] Title:Second harmonic generation from tryptophan-rich short peptides: W(n)K(m) and gramicidin A.
[So] Source:J Phys Chem B;118(35):10413-8, 2014 Sep 04.
[Is] ISSN:1520-5207
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:We report the first hyperpolarizability of a series of tryptophan-rich short peptides with the respective sequence KWK, KWWK, KWWWK, KWWKWWK, where W and K stand for tryptophan and lysine. The measurements were performed with the technique of hyper-Rayleigh scattering in the bulk of an aqueous Tris buffer solution at a pH of 8.5 and a salt concentration of 150 mM at the non-resonant fundamental wavelength of 784 nm. The first hyperpolarizability of the different peptides follows a simple additive model scaling with the number of tryptophan residues contained in the peptide. However, it appears that the first hyperpolarizability response of a single tryptophan residue in the peptide strongly differs from that of an isolated tryptophan. Hence, it is therefore demonstrated that the local environment of the tryptophan residues within the peptide strongly influences its nonlinear optical response. A comparison with the first hyperpolarizability of the natural peptide gramicidin A measured in trifluoroethanol (TFE) further confirms the key role of the local environment on the first hyperpolarizability of tryptophan residues in peptides.
[Mh] MeSH terms primary: Gramicidin/chemistry
Lysine/chemistry
Peptides/chemistry
Tryptophan/chemistry
[Mh] MeSH terms secundary: Hydrogen-Ion Concentration
Ipodate/chemistry
Models, Molecular
Nonlinear Dynamics
Peptides/genetics
Scattering, Radiation
Solutions
Solvents/chemistry
Spectrometry, Fluorescence
Trifluoroethanol/chemistry
Tromethamine/chemistry
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Peptides); 0 (Solutions); 0 (Solvents); 023C2WHX2V (Tromethamine); 1405-97-6 (Gramicidin); 75-89-8 (Trifluoroethanol); 8DUH1N11BX (Tryptophan); F604ZKI910 (Ipodate); K3Z4F929H6 (Lysine)
[Em] Entry month:1505
[Cu] Class update date: 140904
[Lr] Last revision date:140904
[Js] Journal subset:IM
[Da] Date of entry for processing:140822
[St] Status:MEDLINE
[do] DOI:10.1021/jp506416s

  2 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 17450242
[Au] Autor:Mazokopakis EE; Chatzipavlidou V
[Ad] Address:Department of Internal Medicine, Naval Hospital of Crete, Chania, Greece. elmazokopakis@yahoo.gr
[Ti] Title:Hashimoto's thyroiditis and the role of selenium. Current concepts.
[So] Source:Hell J Nucl Med;10(1):6-8, 2007 Jan-Apr.
[Is] ISSN:1790-5427
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:Hashimoto's thyroiditis (HT) is part of the spectrum of autoimmune thyroid diseases. Clinical manifestations of HT are variable and commonly include diffuse or nodular goiter with euthyroidism, subclinical hypothyroidism and permanent hypothyroidism. Uncommonly, HT causes acute destruction of thyroid tissue and release of stored thyroid hormones, causing transient thyrotoxicosis (hashitoxicosis). The contribution of methods and techniques of nuclear medicine to diagnosis and differential diagnosis of HT is indisputable. In HT patients with overt hypothyroidism L-thyroxine (L-T(4)) should be given in the usual replacement doses, but in HT patients with a large goiter and normal or elevated serum thyroid-stimulating hormone (TSH), L-T(4) may be given in doses sufficient to suppress serum TSH. Symptomatic patients with hashitoxicosis and low 24-hour thyroid radioactive iodine ((123)I or (123)I) uptake (RIU) may be treated with beta-blockers (as propranolol) and sodium ipodate or iopanoic acid (iodinated contrast agents) that block the peripheral conversion of T(4) to T(3). Recent clinical studies have documented the suppressive effect of selenium treatment on serum anti-thyroid peroxidase concentrations in patients with HT.
[Mh] MeSH terms primary: Hashimoto Disease/diagnostic imaging
Hashimoto Disease/drug therapy
Selenium/administration & dosage
Thyroxine/administration & dosage
[Mh] MeSH terms secundary: Animals
Clinical Trials as Topic/trends
Dietary Supplements
Humans
Practice Guidelines as Topic
Practice Patterns, Physicians'/trends
Radionuclide Imaging
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:H6241UJ22B (Selenium); Q51BO43MG4 (Thyroxine)
[Em] Entry month:0706
[Cu] Class update date: 161124
[Lr] Last revision date:161124
[Js] Journal subset:IM
[Da] Date of entry for processing:070424
[St] Status:MEDLINE

  3 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 17389703
[Au] Autor:Laurberg P; Vestergaard H; Nielsen S; Christensen SE; Seefeldt T; Helleberg K; Pedersen KM
[Ad] Address:Department of Endocrinology and Medicine, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. peter.laurberg@rn.dk
[Ti] Title:Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases.
[So] Source:J Clin Endocrinol Metab;92(6):2149-56, 2007 Jun.
[Is] ISSN:0021-972X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:CONTEXT: Graves' hyperthyroidism and multinodular toxic goiter lead to high serum T(3) compared with serum T(4). The source of this high T(3) has not been clarified. OBJECTIVE: Our objective was to assess the role of iodothyronine deiodinase type 1 (D1) and type 2 (D2) for T(3) production and to estimate the sources of T(3) in hyperthyroidism. DESIGN AND SETTING: The study was a prospective, randomized, open-labeled study in a secondary care setting. PATIENTS AND METHODS: Consecutive patients with hyperthyroidism caused by Graves' disease or by multinodular toxic goiter were randomized to be treated with high-dose propylthiouracil (PTU) to block D1, PTU plus KI, or PTU plus sodium ipodate to additionally block D2. T(3) and T(4) were measured in serum, and we estimated the sources of T(3). RESULTS: PTU reduced the T(3)/T(4) in serum to 47.7 +/- 2.5% (mean +/- sem) of the initial value on d 4 of therapy in patients with Graves' disease. The addition of KI to PTU led to a greater fall in T(3) and T(4), but the balance was unaltered. After PTU plus ipodate, T(3)/T(4) on d 4 was lower, 34.1 +/- 1.2% of the initial value. Similar variations were observed in patients with multinodular toxic goiter. Thus, the major source of the excess T(3) was D1-catalyzed T(4) deiodination, with a minor role for D2. It was estimated that the majority of this D1-catalyzed T(3) production takes place in the hyperactive thyroid gland. CONCLUSION: Although thyroidal T(3) contributes only around 20% of total T(3) production in normal individuals, this is much higher in patients with a hyperactive thyroid, ranging up to two thirds. The major part is produced from T(4) deiodinated in the thyroid.
[Mh] MeSH terms primary: Antithyroid Agents/administration & dosage
Hyperthyroidism/drug therapy
Hyperthyroidism/metabolism
Iodide Peroxidase/antagonists & inhibitors
Propylthiouracil/administration & dosage
Triiodothyronine/blood
[Mh] MeSH terms secundary: Adolescent
Adult
Child
Drug Therapy, Combination
Female
Goiter, Nodular/drug therapy
Goiter, Nodular/metabolism
Graves Disease/drug therapy
Graves Disease/metabolism
Humans
Iodide Peroxidase/metabolism
Ipodate/administration & dosage
Male
Middle Aged
Prospective Studies
Thyroxine/blood
Treatment Outcome
Triiodothyronine/biosynthesis
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Name of substance:0 (Antithyroid Agents); 06LU7C9H1V (Triiodothyronine); 721M9407IY (Propylthiouracil); EC 1.11.1.- (iodothyronine deiodinase type I); EC 1.11.1.- (iodothyronine deiodinase type II); EC 1.11.1.8 (Iodide Peroxidase); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Entry month:0707
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:070329
[St] Status:MEDLINE

  4 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 12682620
[Au] Autor:Martinez DS; Chopra IJ
[Ad] Address:Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, UCLA Center for Health Sciences, Los Angeles, CA, USA.
[Ti] Title:Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis.
[So] Source:Panminerva Med;45(1):53-7, 2003 Mar.
[Is] ISSN:0031-0808
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:AIM: In this study, we describe our experience in treating subacute thyroiditis patients with 2 OCAs (sodium ipodate and sodium iopanoate). METHODS: We studied 10 consecutive patients with subacute thyroiditis treated with 1 of the 2 oral cholecystography agents (OCAs). RESULTS: Hyperthyroidism was controlled and symptoms improved markedly in each case without any evidence of subsequent relapse of thyroiditis after withdrawal of OCAs. Three of the 10 patients had been treated previously with corticosteroids and had demonstrated relapse of thyroiditis and hyperthyroidism after tapering or withdrawal of steroids. We observed no side effects of treatment with OCAs. CONCLUSION: Our data suggest that OCAs are effective and safe agents for management of hyperthyroidism in patients with subacute thyroiditis, even when they have relapsed after treatment with corticosteroids.
[Mh] MeSH terms primary: Contrast Media/administration & dosage
Hyperthyroidism/drug therapy
Hyperthyroidism/etiology
Iopanoic Acid/analogs & derivatives
Iopanoic Acid/administration & dosage
Ipodate/administration & dosage
Thyroiditis, Subacute/complications
[Mh] MeSH terms secundary: Acute Disease
Administration, Oral
Adult
Aged
Cholecystography
Female
Humans
Male
Middle Aged
[Pt] Publication type:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Name of substance:0 (Contrast Media); F604ZKI910 (Ipodate); FE9794P71J (Iopanoic Acid)
[Em] Entry month:0307
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:IM
[Da] Date of entry for processing:030412
[St] Status:MEDLINE

  5 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 11600529
[Au] Autor:Chopra IJ; Baber K
[Ad] Address:Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, University of California Center for Health Sciences, 900 Veteran Avenue, Los Angeles, CA 90024, USA. ichopra@mednet.ucla.edu
[Ti] Title:Use of oral cholecystographic agents in the treatment of amiodarone-induced hyperthyroidism.
[So] Source:J Clin Endocrinol Metab;86(10):4707-10, 2001 Oct.
[Is] ISSN:0021-972X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:We describe here five cardiac patients with type II amiodarone-induced hyperthyroidism who were treated prospectively with a combination of an oral cholecystographic agent (sodium ipodate, Oragrafin, or sodium iopanoate, Telepaque) and a thionamide (propylthiouracil or methimazole); amiodarone was discontinued in all patients. All patients improved substantially clinically within a few days of treatment and became euthyroid or hypothyroid in 15-31 wk when treatment was discontinued. Four of the five became hypothyroid and required long-term treatment with L-T(4); the remaining patient was euthyroid, but died from cardiomyopathy and congestive heart failure at 29 wk, when he had been off oral cholecystographic agent and thionamide for 6 wk. We did not find any clinical or biochemical adverse effects of the treatment. Our study suggests that a combination of oral cholecystographic agent and thionamide is a safe and effective treatment of type II amiodarone-induced hyperthyroidism. Data also suggest that hypothyroidism is a common end result of type II amiodarone-induced hyperthyroidism.
[Mh] MeSH terms primary: Amiodarone/adverse effects
Anti-Arrhythmia Agents/adverse effects
Antithyroid Agents/administration & dosage
Enzyme Inhibitors/administration & dosage
Hyperthyroidism/drug therapy
Iodide Peroxidase/antagonists & inhibitors
[Mh] MeSH terms secundary: Administration, Oral
Adult
Aged
Cholecystography
Humans
Male
Middle Aged
Prospective Studies
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Anti-Arrhythmia Agents); 0 (Antithyroid Agents); 0 (Enzyme Inhibitors); EC 1.11.1.8 (Iodide Peroxidase); N3RQ532IUT (Amiodarone)
[Em] Entry month:0111
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:011016
[St] Status:MEDLINE

  6 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 11442003
[Au] Autor:Fontanilla JC; Schneider AB; Sarne DH
[Ad] Address:Department of Medicine, University of Illinois at Chicago, USA.
[Ti] Title:The use of oral radiographic contrast agents in the management of hyperthyroidism.
[So] Source:Thyroid;11(6):561-7, 2001 Jun.
[Is] ISSN:1050-7256
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Oral iodinated radiographic contrast agents such as ipodate and iopanoic acid form an important part of the armamentarium used to treat hyperthyroidism. They rapidly and dramatically reduce serum triiodothyronine (T3) levels by inhibiting conversion of thyroxine (T4) to T3 in the periphery and by blocking secretion from the thyroid. Potential risks from the large iodine load resulting from their use limit their widespread applicability. In addition, they are ineffective when used alone on a long-term basis. However, these agents may be especially useful in treating thyrotoxic patients preoperatively, in neonatal Graves' disease, in massive levothyroxine ingestion, and when other conventional antithyroid drugs are unsuccessful or contraindicated.
[Mh] MeSH terms primary: Hyperthyroidism/drug therapy
Iodine Radioisotopes/administration & dosage
[Mh] MeSH terms secundary: Administration, Oral
Animals
Antithyroid Agents/therapeutic use
Dose-Response Relationship, Drug
Humans
Hyperthyroidism/blood
Iodine Radioisotopes/adverse effects
Iodine Radioisotopes/therapeutic use
Thyroid Hormones/physiology
Triiodothyronine/blood
[Pt] Publication type:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.; REVIEW
[Nm] Name of substance:0 (Antithyroid Agents); 0 (Iodine Radioisotopes); 0 (Thyroid Hormones); 06LU7C9H1V (Triiodothyronine)
[Em] Entry month:0112
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:IM
[Da] Date of entry for processing:010710
[St] Status:MEDLINE

  7 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 11318795
[Au] Autor:Davison S; Lennard TW; Davison J; Kendall-Taylor P; Perros P
[Ad] Address:Endocrine Unit, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK.
[Ti] Title:Management of a pregnant patient with Graves' disease complicated by thionamide-induced neutropenia in the first trimester.
[So] Source:Clin Endocrinol (Oxf);54(4):559-61, 2001 Apr.
[Is] ISSN:0300-0664
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:A 31-year-old woman presented with neutropenia due to thionamide drug therapy for Graves' disease. She also reported 8 weeks of amenorrhoea and had a positive pregnancy test. Her drug therapy was discontinued and her neutropenia resolved uneventfully. The hyperthyroidism recurred a week later. After consideration of all treatment options, it was decided to observe until 14 weeks when an elective thyroidectomy was planned. Mother and fetus were monitored closely and both tolerated moderate hyperthyroidism well. At 14 weeks the patient underwent a total thyroidectomy after rendering her euthyroid with a short course of sodium ipodate. Labour was induced at 41 weeks. Delivery was complicated by fetal distress and precipitated a forceps delivery. A 3250 g male infant was born with poor Apgar score and required 2 h of ventilation. At 1 year, the child had reached all developmental milestones at appropriate times. Both mother and fetus may tolerate moderate thyrotoxicosis well in early pregnancy, an alternative that should be considered when thionamide drug therapy is contraindicated.
[Mh] MeSH terms primary: Antithyroid Agents/adverse effects
Graves Disease/drug therapy
Neutropenia/chemically induced
Pregnancy Complications/drug therapy
Propylthiouracil/adverse effects
[Mh] MeSH terms secundary: Adult
Antithyroid Agents/therapeutic use
Female
Graves Disease/surgery
Humans
Infant, Newborn
Male
Pregnancy
Pregnancy Complications/surgery
Pregnancy Outcome
Pregnancy Trimester, First
Pregnancy Trimester, Second
Propylthiouracil/therapeutic use
Thyroidectomy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Antithyroid Agents); 721M9407IY (Propylthiouracil)
[Em] Entry month:0201
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:IM
[Da] Date of entry for processing:010425
[St] Status:MEDLINE

  8 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 9261010
[Au] Autor:Tomaski SM; Mahoney EM; Burgess LP; Raines KB; Bornemann M
[Ad] Address:Department of Surgery, Tripler Army Medical Center, Hawaii 96859-5000, U.S.A.
[Ti] Title:Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism.
[So] Source:Laryngoscope;107(8):1066-70, 1997 Aug.
[Is] ISSN:0023-852X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Fourteen Graves' hyperthyroid patients who had been prepared for surgery with sodium ipodate (SI) 500 mg orally twice daily for 3 days were retrospectively studied. SI was administered in combination with propylthiouracil (10 cases) and beta blockers (all cases), which had been previously initiated. Free serum thyroxine (T4) and total triiodothyronine (T3) concentrations were measured before and after SI therapy on the morning of surgery. SI treatment significantly reduced total T3 concentration from 445.9 to 193.4 ng/dL (P < 0.0001) and free T4 concentration from 3.874 to 2.800 ng/dL (P = 0.0003). Preoperatively, only one patient had persistent tachycardia, and intraoperatively this same patient required beta blockers. Blood loss was unremarkable or reduced (average blood loss, 121 mL). On clinical examination glands were firm with normal or somewhat decreased vascularity. On histologic study all glands demonstrated changes consistent with treated Graves' disease. Preoperative treatment with SI appears to be a safe and efficacious method of preparing hyperthyroid patients for surgery.
[Mh] MeSH terms primary: Antithyroid Agents/therapeutic use
Graves Disease/surgery
Ipodate/therapeutic use
Premedication
Thyroidectomy
[Mh] MeSH terms secundary: Adrenergic beta-Antagonists/therapeutic use
Adult
Antithyroid Agents/pharmacology
Blood Loss, Surgical
Female
Graves Disease/blood
Graves Disease/drug therapy
Humans
Ipodate/pharmacology
Male
Preoperative Care
Propylthiouracil/therapeutic use
Retrospective Studies
Thyroid Gland/drug effects
Thyroid Gland/pathology
Thyrotropin/blood
Thyroxine/blood
Triiodothyronine/blood
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Adrenergic beta-Antagonists); 0 (Antithyroid Agents); 06LU7C9H1V (Triiodothyronine); 721M9407IY (Propylthiouracil); 9002-71-5 (Thyrotropin); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Entry month:9709
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:IM
[Da] Date of entry for processing:970801
[St] Status:MEDLINE

  9 / 188 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 9215413
[Au] Autor:Murray LA; Peterson ME
[Ad] Address:Department of Medicine, Animal Medical Center, New York, NY 10021, USA.
[Ti] Title:Ipodate treatment of hyperthyroidism in cats.
[So] Source:J Am Vet Med Assoc;211(1):63-7, 1997 Jul 01.
[Is] ISSN:0003-1488
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To evaluate the efficacy and safety of ipodate in the treatment of hyperthyroidism in cats. DESIGN: Prospective case series. ANIMALS: 12 cats with hyperthyroidism treated at The Animal Medical Center between November 1994 and March 1996. PROCEDURE: Each cat initially received 100 mg of ipodate/d, PO. The drug's effects on clinical signs, body weight, heart rate, and serum triiodothyronine (T3) and thyroxine concentrations were evaluated 2, 4, 6, 10, and 14 weeks after initiation of treatment. A CBC and serum biochemical analyses were performed at each evaluation to monitor potential adverse effects of the drug. Dosage of ipodate was increased to 150 mg/d and then to 200 mg/d at 2-week intervals if a good clinical response was not observed. RESULTS: 8 cats responded to treatment and 4 did not. Among cats that responded, mean body weight increased and mean heart rate and serum T3 concentration decreased during the study period. Among cats that did not respond, mean body weight decreased and mean heart rate and serum T3 concentration were not significantly changed. Serum thyroxine concentration remained high in all cats. Adverse clinical signs or hematologic abnormalities attributable to ipodate treatment were not reported in any of the cats. CLINICAL IMPLICATIONS: Ipodate may be a feasible alternative to methimazole for medical treatment of hyperthyroidism in cats, particularly those that cannot tolerate methimazole and are not candidates for surgery or radiotherapy. Cats with severe hyperthyroidism are less likely to respond to ipodate than are cats with mild or moderate disease, and cats in which serum T3 concentration does not return to the reference range are unlikely to have an adequate improvement in clinical signs.
[Mh] MeSH terms primary: Cat Diseases/drug therapy
Contrast Media/therapeutic use
Hyperthyroidism/veterinary
Ipodate/therapeutic use
[Mh] MeSH terms secundary: Animals
Cats
Female
Heart Rate
Hyperthyroidism/drug therapy
Male
Prospective Studies
Thyroxine/blood
Triiodothyronine/blood
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Contrast Media); 06LU7C9H1V (Triiodothyronine); F604ZKI910 (Ipodate); Q51BO43MG4 (Thyroxine)
[Em] Entry month:9710
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:IM
[Da] Date of entry for processing:970701
[St] Status:MEDLINE

  10 / 188 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 8952775
[Au] Autor:Mariani R; Bertrand AM; Maillotte AM; Peyrade C; Bortoluzzi MN
[Ad] Address:Service de pédiatrie, hôpital de Cimiez, Nice, France.
[Ti] Title:Traitement de l'hyperthyroïdie néonatale par l'iopodate de calcium. [Treatment of neonatal hyperthyroidism with calcium iopodate].
[So] Source:Arch Pediatr;3(11):1102-6, 1996 Nov.
[Is] ISSN:0929-693X
[Cp] Country of publication:France
[La] Language:fre
[Ab] Abstract:BACKGROUND: Treatment of hyperthyroidism in those neonates born to mothers with Grave's disease is difficult. Calcium ipodate, an agent for oral cholecystography, inhibits extra-thyroid conversion of T3 to T4 and diminishes thyroid secretion. CASE REPORTS: Two neonates with clinical manifestations and biological findings of hyperthyroidism were given calcium ipodate orally, 400 mg every 3 days, from day 26 to 50 for the first patient and from day 9 to 18 for the second in association with a beta blocker. Clinical manifestations disappeared within 2 days and circulating levels of T3 and T4 were normalized within 2-5 days. CONCLUSIONS: This treatment was effective and well-tolerated in both patients and in three others previously reported; it should be confirmed in a larger number of patients and controlled by measuring levels of antibodies directed against thyrotropin-releasing hormone receptors in order to avoid relapse after cessation of treatment as seen in our second patient.
[Mh] MeSH terms primary: Hyperthyroidism/drug therapy
Ipodate/therapeutic use
Triiodothyronine/antagonists & inhibitors
[Mh] MeSH terms secundary: Adrenergic beta-Antagonists/administration & dosage
Adrenergic beta-Antagonists/therapeutic use
Drug Therapy, Combination
Female
Humans
Infant, Newborn
Ipodate/administration & dosage
Propranolol
[Pt] Publication type:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Name of substance:0 (Adrenergic beta-Antagonists); 06LU7C9H1V (Triiodothyronine); 9Y8NXQ24VQ (Propranolol); F604ZKI910 (Ipodate)
[Em] Entry month:9701
[Cu] Class update date: 131121
[Lr] Last revision date:131121
[Js] Journal subset:IM
[Da] Date of entry for processing:961101
[St] Status:MEDLINE


page 1 of 19 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information